Previous 10 | Next 10 |
Image source: The Motley Fool. Neurocrine Biosciences Inc (NASDAQ: NBIX) Q4 2019 Earnings Call Feb 4, 2020 , 4:30 p.m. ET Operator Continue reading
Neurocrine Biosciences, Inc. (NBIX) Q4 2019 Earnings Conference Call February 04, 2020 4:30 PM ET Company Participants Kevin Gorman - Chief Executive Officer Todd Tushla - Head of Investor Relations Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer ...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Neurocrine Biosciences (NASDAQ: NBIX ) Q4 results : More news on: Neurocrine Biosciences, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Neurocrine Biosciences (NASDAQ: NBIX ): Q4 Non-GAAP EPS of $1.05 beats by $0.30 ; GAAP EPS of $0.35 misses by $0.41 . More news on: Neurocrine Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , Feb. 4, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2019 and provided full-year 2020 financial expense guidance. "I am very pleased with the acco...
SAN DIEGO , Feb. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Shalini Sharp to its Board of Directors. Ms. Sharp is the Chief Financial Officer and Executive Vice President of Ultragenyx, a clinical-stage biopharmaceutical compan...
As fears of a global pandemic continue to grip stock markets and crude oil, not even the biotechnology sector ( IBB ) could escape the wrath with IBB declining more than 6% from year-to-date highs. Indeed, although a handful of biotech names such as VIR which are developing vaccines for the...
SAN DIEGO , Jan. 20, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb. 4, 2020 . Neurocrine will then host a conference call and webcast t...
Expectations can be irrational and still have power – that’s about the only reason I can see for why Neurocrine ( NBIX ) shares were as weak as they were coming out of the company’s JPMorgan Healthcare Conference presentation. Investors went into this conference with inf...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...